



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Nattokinase, Natto fermentation

<b>Cat. No.:</b>	HY-P2373		
<b>CAS No.:</b>	133876-92-3		
<b>Target:</b>	Others		
<b>Pathway:</b>	Others		Nattokinase, Natto fermentation
<b>Storage:</b>	Powder	-20°C 3 years 4°C 2 years	
	In solvent	-80°C 6 months -20°C 1 month	

### SOLVENT & SOLUBILITY

<b>In Vitro</b>	H <sub>2</sub> O : 100 mg/mL (Need ultrasonic)
<b>In Vivo</b>	1. Add each solvent one by one: PBS Solubility: 50 mg/mL (Infinity mM); Clear solution; Need ultrasonic

### BIOLOGICAL ACTIVITY

<b>Description</b>	Nattokinase, Natto fermentation is a potent fibrinolytic enzyme. Nattokinase can break down blood clots by directly hydrolyzing fibrin and plasmin substrate. Nattokinase can be used for the research of cardiovascular diseases <sup>[1]</sup> .	
<b>In Vitro</b>	Nattokinase dissolves 94% blood clot at ten minutes and degrades the fibrin clot after two hours of incubation <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
<b>In Vivo</b>	Nattokinase (150-250 mg/kg; oral gavage twice daily for 2 days) exhibits fibrinolytic activity and dissolves blood clots in vivo <sup>[3]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	<b>Animal Model:</b>	Sprague-Dawley (SD) rats (180-220 g) are injected k-Carrageenan <sup>[3]</sup>
	<b>Dosage:</b>	150, 250 mg/kg
	<b>Administration:</b>	Oral gavage twice daily for 2 days
	<b>Result:</b>	Increased the plasma concentration of fibrin/fibrinogen degradation products (FDPs) and D-Dimer in a dose-dependent manner. Decreased the fraction of the vessel cross section occupied by thrombosis.

### CUSTOMER VALIDATION

- 
- BMC Biol. 2023 Dec 10;21(1):290.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

---

- [1]. Weng Y, et, al. Nattokinase: An Oral Antithrombotic Agent for the Prevention of Cardiovascular Disease. *Int J Mol Sci.* 2017 Feb 28; 18(3):523.
- [2]. Chandrasekaran SD, et, al. Exploring the In Vitro Thrombolytic Activity of Nattokinase From a New Strain *Pseudomonas aeruginosa* CMSS. *Jundishapur J Microbiol.* 2015 Oct 26; 8(10): e23567.
- [3]. Xu J, et, al. Thrombolytic effects in vivo of nattokinase in a carrageenan-induced rat model of thrombosis. *Acta Haematol.* 2014; 132(2): 247-53.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA